PMC:7100515 / 669-921 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"T11","span":{"begin":43,"end":47},"obj":"Disease"},{"id":"T12","span":{"begin":83,"end":91},"obj":"Disease"},{"id":"T13","span":{"begin":102,"end":110},"obj":"Disease"},{"id":"T14","span":{"begin":162,"end":166},"obj":"Disease"},{"id":"T15","span":{"begin":171,"end":179},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ss stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recove"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T11","span":{"begin":48,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":"ss stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recove"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":27,"end":129},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ss stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recove"}

{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":113,"end":114},"obj":"Gene"},{"id":"48","span":{"begin":83,"end":91},"obj":"Species"},{"id":"49","span":{"begin":102,"end":112},"obj":"Species"},{"id":"50","span":{"begin":180,"end":188},"obj":"Species"},{"id":"52","span":{"begin":15,"end":23},"obj":"Species"},{"id":"54","span":{"begin":171,"end":179},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Gene:43740568"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:694009"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:2697049"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:694009"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ss stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recove"}